key: cord-0716291-jvgq2p61
authors: Muik, Alexander; Wallisch, Ann-Kathrin; Sänger, Bianca; Swanson, Kena A.; Mühl, Julia; Chen, Wei; Cai, Hui; Sarkar, Ritu; Türeci, Özlem; Dormitzer, Philip R.; Sahin, Ugur
title: Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera
date: 2021-01-19
journal: bioRxiv
DOI: 10.1101/2021.01.18.426984
sha: 161ed0d7cf8400db6005741982607f15b03b1aea
doc_id: 716291
cord_uid: jvgq2p61

Recently, a new SARS-CoV-2 lineage called B.1.1.7 has emerged in the United Kingdom that was reported to spread more efficiently than other strains. This variant has an unusually large number of mutations with 10 amino acid changes in the spike protein, raising concerns that its recognition by neutralizing antibodies may be affected. Here, we investigated SARS-CoV-2-S pseudoviruses bearing either the Wuhan reference strain or the B.1.1.7 lineage spike protein with sera of 16 participants in a previously reported trial with the mRNA-based COVID-19 vaccine BNT162b2. The immune sera had equivalent neutralizing titers to both variants. These data, together with the combined immunity involving humoral and cellular effectors induced by this vaccine, make it unlikely that the B.1.1.7 lineage will escape BNT162b2-mediated protection.

2 involving humoral and cellular effectors induced by this vaccine, make it unlikely that the B.1.1.7 lineage will escape BNT162b2-mediated protection.

In a pivotal phase 3 trial conducted in the United States, Argentina, Brazil, South Africa, 5 Germany, and Turkey, the BioNTech-Pfizer mRNA vaccine BNT162b2 was 95% effective in preventing COVID-19 through the data cut-off date of November 14, 2020 (1). In September 2020, the SARS-CoV-2 lineage B.1.1.7 was detected in the United Kingdom (2), and it subsequently increased in prevalence, showed enhanced transmissibility, and spread to other countries and continents (3). B.1.1.7 has a series of mutations in its spike 10 (S) protein: ΔH69/V70, ΔY144, N501Y, A570D, D614G, P681H, T716I, S982A, and D1118H. One of these mutations, N501Y, was of particular concern because it is located in the receptor binding site, the spike with this mutation binds more tightly to its cellular receptor, ACE-2 (4); and virus with this mutation has an increased host range that includes mice (5) . BNT162b2-immune sera neutralized SARS-CoV-2 (USA/WA-1/2020 15 background strain) with an introduced N501Y mutation as efficiently as SARS-CoV-2 without the mutation (6). Further, 19 pseudoviruses, each bearing a SARS-CoV-2 S with a different mutation found in circulating strains, were also neutralized as efficiently as nonmutant SARS-CoV-2 S bearing pseudoviruses by BNT162b2-immune sera (7) . To answer this question, we generated VSV-SARS-CoV-2-S pseudoviruses bearing the Wuhan reference strain or the lineage B.1.1.7 spike protein ( Fig S1) . Sera of 16 3 participants in the previously reported German phase 1/2 trial (7), drawn from eight younger (18-55 yrs) and eight older adults (56-85 yrs) at 21 days after the booster immunization with 30 µg BNT162b2 (Fig S2) , were tested for neutralization of SARS-CoV-2 Wuhan and lineage B.1.1.7 spike-pseudotyped VSV by a 50% neutralization assay (pVNT 50 ). The ratio of the 50% neutralization geometric mean titer (GMT) of the sera 5 against the SARS-CoV-2 lineage B.1.1.7 spike-pseudotyped VSV to that against the Wuhan reference spike-pseudotyped VSV was 0.79, indicating no biologically significant difference in neutralization activity against the two pseudoviruses ( Fig. 1, Fig. S3 , Table   S1 ).

The preserved neutralization of pseudoviruses bearing the B.1.1.7 spike by BNT162b2-10 immune sera makes it very unlikely that the UK variant viruses will escape BNT162b2mediated protection. A potential limitation of the work may be the use of a non-replicating pseudovirus system. However, previous reports have shown good concordance between pseudotype neutralization and SARS-CoV-2 neutralization assays (8, 9) . Additional 

The data that support the findings of this study are available from the corresponding author upon reasonable request. 

Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding

Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy

Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccineelicited sera

BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. medRxiv (2020)

Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-15

and a Clinical Isolate of SARS-CoV-2

BNT162b vaccines are immunogenic and protect non-human primates against SARS-CoV-2. bioRxiv